Pharmacogenetics Testing Company Focused on Pain Management
The company is the first and only company focused on using genetics for pain management, providing clients with useful insights about compatibility for pain and related treatment. The company looks specifically at 116 variants on 55 genes to make a targeted profile of how the body uses or breaks down medicine, thereby providing a substantial improvement to the 'trial and error' approach currently used by doctors.
It's the only pain management decision support tool covering:
-Comprehensive prescription and non-prescription drugs
-Treatments for related co-morbidities such as mental health/mood disorders
-Personal cannabis metabolism with 9 recommendation profiles
The test also covers comprehensive research-based findings on the genetic basis of opioid and cannabis dependency. The test is commercially available and management anticipates being profitable by the end of 2020. The company is currently focused on the Canadian market but management has planned for international expansion in the medium-term.
We have invested CA$2M and are looking for other investors to invest CA$3.5-5M alongside us.
Minett Capital is a privately held management firm founded by Alan Greenberg that oversees and manages a diverse set of assets and investments across a range of sectors, including real estate, venture capital and health. We have extensive experience in real estate development, early stage startups, and business restructuring and transformation. We focus on connecting high net worth families and private investors with attractive investment opportunities in Canada, Israel, Europe, and the United States.